What is the prognosis of endometrioid adenocarcinoma of the uterus compared to ovarian adenocarcinoma?

Endometrioid Adenocarcinoma of the Uterus Has a Significantly Better Prognosis Than Ovarian Adenocarcinoma

Endometrioid adenocarcinoma of the endometrium carries a substantially more favorable prognosis compared to ovarian adenocarcinoma, with 5-year survival rates of approximately 83% for endometrial tumors versus 53% for ovarian papillary carcinomas and 62% for ovarian clear-cell carcinomas 1.

Key Prognostic Differences

Endometrial Endometrioid Adenocarcinoma

The prognosis for endometrial cancer is generally excellent, particularly for the endometrioid subtype which represents 80-90% of cases 2:

• Overall 5-year survival: 76-78% across all stages 1
• Stage I disease: 80% of patients present at this early stage 3
• Stage IA survival: 89.6% 1
• Stage IB survival: 77.6% 1

Type I endometrioid tumors are typically estrogen-dependent, low-grade (grades 1-2), preceded by endometrial hyperplasia, and associated with better outcomes 3. Even when comparing high-risk subgroups, endometrial cancer maintains relatively favorable survival rates.

Ovarian Adenocarcinoma

Ovarian cancer demonstrates markedly worse outcomes:

• Serous carcinoma 5-year survival: 53% 1
• Clear-cell carcinoma 5-year survival: 62% 1
• Advanced disease at presentation: 60-70% of uterine serous cancers (which behave similarly to ovarian primaries) have extrauterine disease at diagnosis 2

The critical distinction is that ovarian cancers are more frequently diagnosed at advanced stages with regional or distant spread, resulting in 5-year survival rates of only 68% for regional disease and 17% for distant metastases 2.

Special Consideration: Synchronous Tumors

When endometrioid adenocarcinoma occurs simultaneously in both the endometrium and ovary, the prognosis depends critically on whether these represent two independent primary tumors versus metastatic disease 4:

• Independent synchronous primaries: 75-80% 5-year survival 4
• Metastatic disease: 30-40% 5-year survival 4
• Synchronous tumors confined to uterus and ovary: 5-year recurrence risk of only 10% 5

Patients with synchronous endometrioid tumors are typically younger, present with low-grade, early-stage disease, and have excellent outcomes—particularly when disease is microscopically limited to the uterus and ovary 5. The estimated 5-year survival for these patients reaches 85.9%, with 10-year survival of 80.3% 5.

Clinical Implications

The fundamental prognostic advantage of endometrial endometrioid adenocarcinoma stems from three factors:

1. Early detection: 80% present as stage I disease due to early symptom onset (abnormal bleeding)
2. Favorable biology: Type I endometrioid tumors are inherently less aggressive
3. Surgical accessibility: Complete surgical staging and resection is more readily achievable

In contrast, ovarian adenocarcinomas typically present at advanced stages with peritoneal dissemination, making complete cytoreduction more challenging and outcomes substantially worse. The 5-year survival difference of approximately 30 percentage points between endometrial endometrioid and ovarian serous/clear-cell carcinomas represents one of the most significant prognostic disparities in gynecologic oncology 1.